drugset / Trial / NCT04237584
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
Phase 3
Terminated
23 enrolled
MANA RBM
Barbara Ann Karmanos Cancer Institute · collabBayer · collabCarolina Urologic Research Center · collabTulane University · collab
RandomizedSequentialDouble-blindTreatment
Summary
This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2022-03-07
- Completion
- 2022-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darolutamide | Other / unclassified | 300 mg | Oral |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Comparator | Radium-223 dichloride | Other / unclassified | 0.055 mbq/kg | Intravenous |